desonide (Rx)

Brand and Other Names:Desonate, DesOwen, more...Tridesilon, Verdeso
  • Print

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.05%

foam

  • 0.05%

gel

  • 0.05%

Dermatoses

Cream/ointment/lotion: Apply sparingly to affected area(s) q8-12hr; discontinue therapy if control achieved and reassess diagnosis if no improvement within 4 weeks

Gel or foam: Apply q12hr

Dosage Forms & Strengths

cream/lotion/ointment

  • 0.05%

foam

  • 0.05%

gel

  • 0.05%

Dermatoses

<3 years: Safety and efficacy not established

≥3 years: Apply foam or gel sparingly to affected area(s) q8-12hr; discontinue therapy if control achieved and reassess diagnosis if no improvement within 4 weeks

Next:

Adverse Effects

Frequency Not Defined

Skin atrophy

Striae

Hypertension

Headache

Irritability

Hyperglycemia

Itching

Scaly skin

Acneform lesions

Pigmentation changes

HPA suppression (with higher potency used >2 wk)

Previous
Next:

Warnings

Contraindications

None

Cautions

Shown to reversibly suppress the HPA axis; children may exhibit greater susceptibility to corticosteroid-induced HPA axis suppression and Cushing syndrome due to larger skin surface area to body weight ratio

Use medium-to-very high potency topical corticosteroids for <2 wk to reduce local and systemic adverse effects; avoid use on face, folds, groin owing to increased absorption

Use low potency topical corticosteroids for chronic therapy

May cause local skin adverse reactions; if irritation develops, discontinued and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noticing a clinical exacerbation; corroborate with appropriate diagnostic patch testing

If concomitant skin infections are present or develop, initiate appropriate antifungal, antibacterial, or antiviral agent; if favorable response does not occur promptly, discontinue desonide until infection controlled

Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma

Avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation

Previous
Next:

Pregnancy & Lactation

Pregnancy

There are no available data on use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Animal data

  • In animal reproduction studies, topical administration (cream 0.05%) during organogenesis caused malformations characteristic of corticosteroids in rats and in rabbits; available data do not allow calculation of relevant comparisons of systemic exposure between animals and humans after topical use

Lactation

There are no data on presence in human or animal milk, effects on breastfed infant, or on milk production; unknown whether topical administration could result in sufficient systemic absorption to produce detectable quantities in human milk; developmental and health benefits should be considered along with mother’s clinical need for therapy and any potential adverse effects on breastfed infant from therapy or from the underlying maternal condition

To minimize potential exposure to breastfed infant via breast milk, use on smallest area of skin and for shortest duration possible while breastfeeding; advise breastfeeding women to wash off any amount that may have been applied to nipple and areola prior to breastfeeding to avoid direct infant exposure

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Corticosteroids decrease inflammation by stabilizing leukocyte lysosomal membranes, preventing release of destructive acid hydrolases from leukocytes; inhibiting macrophage accumulation in inflamed areas; reducing leukocyte adhesion to capillary endothelium; reducing capillary wall permeability and edema formation; decreasing complement components; antagonizing histamine activity and release of kinin from substrates; reducing fibroblast proliferation, collagen deposition, and subsequent scar tissue formation

Pharmacokinetics

Absorption: Dependent on nature of skin at application; occlusion and inflammation may increase absorption

Metabolism: Liver

Excretion: Primarily urine

Previous
Next:

Images

Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.